InspireMD Inc Stock News

- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 -

MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “In...

- Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026. Recent Business Highlights: Gene...

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 221,666 shares of restricted stock (the “In...

Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime

MIAMI, June 12, 2026 (GLOBE NEWSWIRE) --  InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to six (6) new non-executive employees in the aggregate amount of 91,161 shares of restricted stock (...

MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80cm implant for use in transcarotid artery revascularization (TCAR) procedures. InspireMD anticipates potential approval...